Companies › Hangzhou Highlightll Pharmaceutical
2 active drug programs in 3 registered trials: 2 Phase 3, 1 Phase 1; Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TLL-018 H1-receptor antagonist | – | Phase 3 | Chronic Spontaneous Urticaria; Rheumatoid Arthritis | Dec 2026 |
| HL-300 | – | Phase 1 | Atopic Dermatitis | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06396026 | TLL-018 | Phase 3 | Chronic Spontaneous Urticaria | Immunology | Dec 2026 |
| NCT06887127 | TLL-018 | Phase 3 | Rheumatoid Arthritis | Immunology | Dec 2026 |
| NCT07629778 | HL-300 | Phase 1 | Atopic Dermatitis | Immunology | Jun 2027 |
No annotated target.
–
Prime Gene Therapeutics Sagimet Biosciences BioCryst Pharmaceuticals Arthrosi Therapeutics Paradigm Biopharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.